Back to Search Start Over

CircZFR serves as a prognostic marker to promote bladder cancer progression by regulating miR-377/ZEB2 signaling.

Authors :
Zhang WY
Liu QH
Wang TJ
Zhao J
Cheng XH
Wang JS
Source :
Bioscience reports [Biosci Rep] 2019 Dec 20; Vol. 39 (12).
Publication Year :
2019

Abstract

Circular RNAs (circRNAs) have been identified as crucial regulators of gene expression in human cancer biology. CircZFR is a novel identified circRNA and its effect in bladder cancer remains unclearly. In the present study, we aimed to investigate the role of circZFR in the progression of bladder cancer. First, we demonstrated that the expression of circZFR was higher in bladder cancer tissues and cells compared with adjacent non-tumor tissues and normal bladder epithelial cells. And higher circZFR levels were positively correlated with bladder cancer patients' pathological T stage, grade, lymphatic metastasis, recurrence, progression-free survival (PFS) and overall survival (OS). Functionally, knockdown of circZFR could significantly prohibit cell growth, migration and invasion, arrest cell cycle as well as promote apoptosis of bladder cancer cells in vitro study. Mechanistically, we observed that circZFR could directly bind to miR-377 as sponge to promote ZEB2 expression in bladder cancer cells. In addition, rescue assays demonstrated that restoration of ZEB2 significantly impaired the suppressive effects of circZFR silencing on bladder cancer cells growth, migration and invasion. Taken together, our results illuminated that circZFR could be a prognostic biomarker in bladder cancer and exerted oncogenic roles through regulating miR-377/ZEB2 axis in bladder cancer, which indicated that circZFR could be a potential therapeutic target for bladder cancer patients treatment.<br /> (© 2019 The Author(s).)

Details

Language :
English
ISSN :
1573-4935
Volume :
39
Issue :
12
Database :
MEDLINE
Journal :
Bioscience reports
Publication Type :
Academic Journal
Accession number :
31746333
Full Text :
https://doi.org/10.1042/BSR20192779